SCHEMBL2380323

SCHEMBL2380323

CNc1n[nH]c2cc(B3OC(C)(C)C(C)(C)O3)ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 2/20 0.42
WDR77 Q9BQA1 2/20 0.42
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA3 P07451 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
EGFR P00533 2/20 0.37
GSK3A P49840 1/20 0.37
GSK3B P49841 1/20 0.37
LPL P06858 5/20 0.36
LIPG Q9Y5X9 5/20 0.36
DYRK1A Q13627 1/20 0.35
HIF1A Q16665 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11182 0.81 PRMT5 (0.42) PRMT5WDR77CA12CA1CA2
SCHEMBL17677977 0.81 PDPK1 (0.46) PRMT5WDR77CA12CA1CA2
SCHEMBL15333263 0.80 LPL (0.44) PRMT5WDR77CA12CA1CA2
SCHEMBL21025741 0.80 PRMT5 (0.41) PRMT5WDR77CA12CA1CA2
SCHEMBL23165855 0.78 YTHDC1 (0.52) PRMT5WDR77CA12CA1CA2
SCHEMBL29850421 0.78 YTHDC1 (0.52) PRMT5WDR77CA12CA1CA2
SCHEMBL22408428 0.78 CSF1R (0.40) PRMT5WDR77CA12CA1CA2
SCHEMBL15288236 0.78 PRMT5 (0.40) PRMT5WDR77CA12CA1CA2
SCHEMBL16440186 0.76 PRMT5 (0.39) PRMT5WDR77CA12CA1CA2
SCHEMBL19896283 0.74 LPL (0.46) PRMT5WDR77CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8987275-B2 Indazole compounds and their uses DANA-FARBER CANCER INSTITUTE, INC. (US) 2015-03-24 US disclosed
US-8987275-B2 Indazole compounds and their uses DANA-FARBER CANCER INSTITUTE, INC. (US) 2015-03-24 US disclosed
US-20130184287-A1 INDAZOLE COMPOUNDS AND THEIR USES DANA-FARBER CANCER INSTITUTE, INC. (US) 2013-07-18 US disclosed
US-20130184287-A1 INDAZOLE COMPOUNDS AND THEIR USES DANA-FARBER CANCER INSTITUTE, INC. (US) 2013-07-18 US disclosed
EP-2547661-A2 INDAZOLE COMPOUNDS AND THEIR USES Dana-Farber Cancer Institute, Inc. (US) 2013-01-23 EP disclosed
WO-2011115725-A2 INDAZOLE COMPOUNDS AND THEIR USES DANA-FARBER CANCER INSTITUTE, INC. (US) 2011-09-22 WO disclosed
WO-2011115725-A2 INDAZOLE COMPOUNDS AND THEIR USES DANA-FARBER CANCER INSTITUTE, INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184287-A1 INDAZOLE COMPOUNDS AND THEIR USES OAT, CYP3A43, CYP11B2 PRMT5 1847/4885WDR77 3869/4885CA12 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.